RAMON RAVELO: Open Payments
NPI 1437172426 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,033 in 126 payments from 13 companies in 2025. Trend: 2023 $2,174 · 2024 $2,661 · 2025 $3,033
Food & beverage: $2,854Education: $179
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 21 | $538 |
| Vanda Pharmaceuticals Inc. | 16 | $531 |
| ABBVIE INC. | 23 | $472 |
| Axsome Therapeutics, Inc. | 10 | $424 |
| Alkermes, Inc. | 19 | $315 |
| Neurocrine BioSciences, Inc. | 9 | $218 |
| Otsuka America Pharmaceutical, Inc. | 13 | $201 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $86 |
| Validus Pharmaceuticals LLC | 3 | $69 |
| Lundbeck LLC | 3 | $59 |
Products named: VRAYLAR, Auvelity, AUSTEDO XR, ARISTADA, HETLIOZ, FANAPT, INGREZZA, ABILIFY ASIMTUFII.
Industry payments across NY — which companies pay providers there.
